Skip to main content
Premium Trial:

Request an Annual Quote

Time to 'Recharge'

Jeff Kindler is retiring after four-and-a-half years as CEO of Pfizer, reports The Wall Street Journal. In a statement, Kindler said that his time there was "extremely exciting and rewarding" though also "extremely demanding" on him personally. "I am excited at the opportunity to recharge my batteries, spend some rare time with my family, and prepare for the next challenge in my career," Kindler said.

The announcement, made Sunday evening, came as a surprise. Analyst Tim Anderson tells The New York Times that he doesn't think there was any "one event per se that caused Kindler's departure." Barbara Ryan, an analyst with another firm, adds that she "heard .. it was a mutual decision," while Erik Gordon says that the company's board may be looking for an executive who is experienced in pharma — Kindler came to Pfizer from McDonald's.

Kindler is being succeeded by Ian Read, who was previously in charge of the company's sales and marketing. At In the Pipeline, Derek Lowe notes that Read has his work cut out for him. "It's hard to see how changing CEOs is going to affect things much. The company is way too huge, and Lipitor is still going off patent," he writes, later adding: "I wish Read luck. But I wouldn't run Pfizer, not for what twice they're paying him."

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.